JP5892612B2 - 疾患の処置に有用な新規のｍｅｋ阻害剤 - Google Patents

疾患の処置に有用な新規のｍｅｋ阻害剤 Download PDF

Info

Publication number
JP5892612B2
JP5892612B2 JP2012534327A JP2012534327A JP5892612B2 JP 5892612 B2 JP5892612 B2 JP 5892612B2 JP 2012534327 A JP2012534327 A JP 2012534327A JP 2012534327 A JP2012534327 A JP 2012534327A JP 5892612 B2 JP5892612 B2 JP 5892612B2
Authority
JP
Japan
Prior art keywords
compound
cancer
mmol
solution
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012534327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507453A5 (cg-RX-API-DMAC7.html
JP2013507453A (ja
Inventor
アール． キレ，ウダイ
アール． キレ，ウダイ
デヴィチャンド コーディア，マヘンドラ
デヴィチャンド コーディア，マヘンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allomek Therapeutics LLC
Original Assignee
Allomek Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allomek Therapeutics LLC filed Critical Allomek Therapeutics LLC
Publication of JP2013507453A publication Critical patent/JP2013507453A/ja
Publication of JP2013507453A5 publication Critical patent/JP2013507453A5/ja
Application granted granted Critical
Publication of JP5892612B2 publication Critical patent/JP5892612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2012534327A 2009-10-13 2010-10-13 疾患の処置に有用な新規のｍｅｋ阻害剤 Active JP5892612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25093609P 2009-10-13 2009-10-13
US61/250,936 2009-10-13
PCT/US2010/052514 WO2011047055A2 (en) 2009-10-13 2010-10-13 Novel mek inhibitors, useful in the treatment of diseases

Publications (3)

Publication Number Publication Date
JP2013507453A JP2013507453A (ja) 2013-03-04
JP2013507453A5 JP2013507453A5 (cg-RX-API-DMAC7.html) 2013-11-28
JP5892612B2 true JP5892612B2 (ja) 2016-03-23

Family

ID=43876849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534327A Active JP5892612B2 (ja) 2009-10-13 2010-10-13 疾患の処置に有用な新規のｍｅｋ阻害剤

Country Status (10)

Country Link
US (1) US9034861B2 (cg-RX-API-DMAC7.html)
EP (1) EP2488507B1 (cg-RX-API-DMAC7.html)
JP (1) JP5892612B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120094165A (cg-RX-API-DMAC7.html)
CN (1) CN102666512B (cg-RX-API-DMAC7.html)
AU (1) AU2010306830C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2814617C (cg-RX-API-DMAC7.html)
ES (1) ES2534358T3 (cg-RX-API-DMAC7.html)
WO (1) WO2011047055A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CA3072856A1 (en) 2017-08-23 2019-02-28 Cell Receptor AG Combination of a mapk/erk pathway inhibitor and a glycosaminoglycan for the treatment of cancer
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4263501A1 (en) * 2020-12-16 2023-10-25 ABM Therapeutics Corporation Kinase inhibitors and uses thereof
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
CN118973580A (zh) 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
IL330382A (en) 2024-01-05 2026-08-01 Pasithea Therapeutics Corp Stereoisomers of 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazepine-3,1'-cyclopropane] 2,2-dioxide, as well as compositions containing them and methods of using them
IL330371A (en) 2024-01-05 2026-08-01 Pasithea Therapeutics Corp Solid forms containing (5R,6S)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazepine-3,1'-cyclopropane] 2,2-dioxide, as well as compositions containing the same and methods of using the same
WO2026112507A1 (en) 2024-11-22 2026-05-28 Pasithea Therapeutics Corp. Tablet formulations and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
GB0131034D0 (en) * 2001-12-28 2002-02-13 Pharmacia & Upjohn Spa Benzocyclodecane derivatives with antitumor activity
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
CN101495118B (zh) 2005-07-21 2012-09-05 阿迪亚生命科学公司 Mek的n-(芳基氨基)磺酰胺抑制剂
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
AU2007237901B2 (en) 2006-04-18 2012-07-05 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
CN103479604B (zh) 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009049642A1 (en) 2007-10-16 2009-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
CN102131771A (zh) 2008-04-14 2011-07-20 阿迪生物科学公司 组合物及其制备和使用方法
CN102134218A (zh) 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂

Also Published As

Publication number Publication date
CA2814617A1 (en) 2011-04-21
WO2011047055A3 (en) 2011-08-18
AU2010306830B2 (en) 2014-11-06
EP2488507A2 (en) 2012-08-22
CA2814617C (en) 2017-12-19
WO2011047055A2 (en) 2011-04-21
CN102666512B (zh) 2014-11-26
EP2488507B1 (en) 2014-12-17
WO2011047055A8 (en) 2012-05-24
ES2534358T3 (es) 2015-04-21
CN102666512A (zh) 2012-09-12
EP2488507A4 (en) 2013-05-01
KR20120094165A (ko) 2012-08-23
US20120208859A1 (en) 2012-08-16
AU2010306830A1 (en) 2012-05-31
BR112012008599A2 (pt) 2019-09-24
US9034861B2 (en) 2015-05-19
AU2010306830C1 (en) 2015-05-28
JP2013507453A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
US9034861B2 (en) MEK inhibitors useful in the treatment of diseases
ES2354182T3 (es) Piridona sulfonamidas y piridona sulfamidas como inhibidores de mek.
ES2543608T3 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de MEK
US7842836B2 (en) N-aryl-N'alkyl sulfamides as MEK inhibitors
NZ582929A (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
US20170183333A1 (en) Derivatives of n-(arylamino) sulfonamides as inhibitors of mek
JP2013545750A (ja) Ｎａｍｐｔ阻害剤
US20150250762A1 (en) Novel mek inhibitors for treating cardiomyopathies and related conditions
HK1174619A (en) Novel mek inhibitors, useful in the treatment of diseases
HK40055242A (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160218

R150 Certificate of patent or registration of utility model

Ref document number: 5892612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250